Brown Richard, Howard Robert, Candy Bridget, Sampson Elizabeth L
Community Mental Health Team for Older People, Kent and Medway NHS Partnership Trust, Gregory House, Littlebourne Road, Canterbury, Kent, UK, CT1 1TD.
Cochrane Database Syst Rev. 2015 May 14;2015(5):CD009705. doi: 10.1002/14651858.CD009705.pub2.
Agitation is a common experience for people living with dementia, particularly as day-to-day function and cognition start to decline more. At the present time there are limited pharmacological options for relieving agitation and little is known about the safety and efficacy of opioid drugs in this setting.
To determine the clinical efficacy and safety of opioids for agitation in people with dementia.
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 13 June 2014 using the terms: narcotic OR opioid OR opium OR morphine OR buprenorphine OR codeine OR dextromoramide OR diphenoxylate OR dipipanone OR dextropropoxyphene OR propoxyphene OR diamorphine OR dihydrocodeine OR alfentanil OR fentanyl OR remifentanil OR meptazinol OR methadone OR nalbuphine OR oxycodone OR papaveretum OR pentazocine OR meperidine OR pethidine OR phenazocine OR hydrocodone OR hydromorphone OR levorphanol OR oxymorphone OR butorphanol OR dezocine OR sufentanil OR ketobemidone.ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases such as MEDLINE, EMBASE and PscyINFO, as well as numerous trial registries and grey literature sources.
Randomised, controlled trials of opioids compared to placebo for agitation in people with dementia.
Two authors independently assessed the studies identified by the search against the inclusion criteria.
There are currently no completed randomised, placebo controlled trials of opioids for agitation in dementia. There are two potentially relevant trials still in progress.
AUTHORS' CONCLUSIONS: We found insufficient evidence to establish the clinical efficacy and safety of opioids for agitation in people with dementia. There remains a lack of data to determine if or when opioids either relieve or exacerbate agitation. More evidence is needed to guide the effective, appropriate and safe use of opioids in dementia.
激越对于痴呆患者来说是一种常见体验,尤其是在日常功能和认知开始进一步衰退时。目前,缓解激越的药物选择有限,对于阿片类药物在这种情况下的安全性和疗效知之甚少。
确定阿片类药物对痴呆患者激越症状的临床疗效和安全性。
我们于2014年6月13日在ALOIS(Cochrane痴呆与认知改善小组专业注册库)中进行检索,检索词如下:麻醉药、阿片类药物、鸦片、吗啡、丁丙诺啡、可待因、右吗拉胺、地芬诺酯、二苯哌己酮、右丙氧芬、丙氧芬、海洛因、二氢可待因、阿芬太尼、芬太尼、瑞芬太尼、美普他酚、美沙酮、纳布啡、羟考酮、阿片全碱、喷他佐辛、哌替啶、非那佐辛、氢可酮、氢吗啡酮、左啡诺、羟吗啡酮、布托啡诺、地佐辛、舒芬太尼、凯托米酮。ALOIS包含从多个主要医疗保健数据库(如MEDLINE、EMBASE和PsycINFO)的月度检索中识别出的临床试验记录,以及众多试验注册库和灰色文献来源。
与安慰剂相比,针对痴呆患者激越症状使用阿片类药物的随机对照试验。
两位作者独立对照纳入标准评估检索所识别出的研究。
目前尚无关于阿片类药物治疗痴呆患者激越症状的完整随机安慰剂对照试验。有两项潜在相关试验仍在进行中。
我们发现没有足够的证据来确定阿片类药物对痴呆患者激越症状的临床疗效和安全性。仍然缺乏数据来确定阿片类药物是否以及何时能缓解或加重激越症状。需要更多证据来指导在痴呆治疗中有效、合理且安全地使用阿片类药物。